A question of control? Next steps for novel TIL therapeutics

Cell & Gene Therapy Insights 2021; 7(10), 1447–1454


Published: 17 November 2021
Jan ter Meulen MD PhD

Jan ter Meulen is a biotech executive (MD, PhD Virology, Board Certified Clin Microbiologist, Diploma Trop Med) with broad experience in immuno-oncology, vaccines, recombinant antibodies and infectious disease R&D, from discovery through phase II clinical trials. He has 16 years of industry experience in leadership positions, including 11 years at biotech companies (CSO at Immune Design Corp. and Executive Director at Crucell Holland NV) and 5 years in pharma (Executive Director & Head of Vaccine Basic Research Department at Merck & Co.). He has conducted extensive cross-functional work in the field of antibodies and vaccines, including discovery research, preclinical development, process development, clinical development, regulatory affairs, and business development. Jan was recipient of a 5-year Howard Hughes International Research Scholarship, and has been a reviewer/consultant for the NIH, European Commission, German Ministry of Science and Education, French Research Agency, Medical Research Council UK, and South Africa.